Frontrunner in Translation: Progressive Supranuclear Palsy
- 1Mashhad University of Medical Sciences, Iran
- 2Department of Neuroscience, University of California, San Diego, United States
Progressive supranuclear palsy (PSP) is a four-repeat tau proteinopathy. Abnormal tau deposition is not unique for PSP and is the basic pathologic finding in some other neurodegenerative disorders such as Alzheimer’s disease (AD), age-related tauopathy, frontotemporal degeneration, corticobasal degeneration and chronic traumatic encephalopathy. While AD research has mostly been focused on amyloid beta pathology until recently, PSP as a prototype of a primary tauopathy with high clinical-pathologic correlation and a rapid course is a crucial candidate for tau therapeutic research. Several novel approaches to slow disease progression are being developed. It is expected that the benefits of translational research in this disease will extend beyond the PSP population. This article reviews advances in the diagnosis, epidemiology, pathology, hypothesized etiopathogenesis, and biomarkers and disease-modifying therapeutic approaches of PSP that is leading it to become a frontrunner in translation.
Keywords: Progressive Supranuclear Palsy, Tauopathy, Translational research, Epidemiology, etiopathogenesis, biomarker -! -
Received: 26 Aug 2019;
Accepted: 08 Oct 2019.
Copyright: © 2019 Shoeibi, Olfati and Litvan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Irene Litvan, Department of Neuroscience, University of California, San Diego, La Jolla, 92093, California, United States, firstname.lastname@example.org